Association of diabetes, homocysteine, and HDL with cognition and disability after stroke

Neurology

Volumn 69, Issue 22, 2007, Pages 2054-2062

  Newman, George C ^a   Bang, Heejung ^b   Hussain, Syed I ^c   Toole, James F ^d  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; VITAMIN;

ADULT; ARTICLE; COGNITION; CONVALESCENCE; DIABETES MELLITUS; DISABILITY; FEMALE; FOLLOW UP; HUMAN; LEFT HEMISPHERE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC STRESS; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RACE; RANKIN SCALE; RECURRENT DISEASE; RISK FACTOR; STROKE;

EID: 36448989357     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000280457.29680.9c     Document Type: Article

References (56)

1. Ingles JL, Wentzel C. Neuropsychological predictors of incident dementia in patients with vascular cognitive impairment, without dementia. Stroke 2002;33:1999-2002.
2. Meyer JS, Xu G, Thornby J, et al. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease? Stroke 2002;33:1981-1985.
3. Vemeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-1222.
4. Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, et al. Post-stroke dementia. Clinical features and risk factors. Stroke 2000;31:1494-1501.
5. Chao CL, Kuo TL, Lee YT. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation 2000;101:485-490.
6. Dayal S, Arning E, Bottiglieri T, et al. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke 2004;35:1957-1962.
7. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923-5928.
8. Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6926.
9. Barter PJ, Nicholls S, Rye K, et al. Anti-inflammatory properties of HDL. Circ Res 2004;95:764-872.
10. Lee CM, Chien CT, Chang PY, et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity. Atherosclerosis 2005;183:251-258.
11. Yuhanna IS, Yan Z, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001;7:853-857.
12. Kim-Mitsuyama S, Yamamoto E, Tanaka T. Critical role of angiotensin II in excess salt induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. Stroke 2005;36:1077-1082.
13. Ito T, Nishimura Y, Saavedra JM. Pre-treatment with candesartan protects from cerebral ischemia. J Renin Ang Aldost Syst 2001;2:174-179.
14. Nishimura Y, Ito T, Saavedra JM. Angiotensin IIAT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000;31:2478-2486.
15. Ando H, Zhou J, Macota M, et al. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004;25:1726-1731.
16. Toole JF, Malinow MR, Chambless LE, et al. Lowering tHcy in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
17. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer, 2000.
18. Diggle PJ, Heagerty P, Liang KY, et al. The analysis of longitudinal data. 2nd Ed. Oxford: Oxford University Press, 2002.
19. Jones S, Jonsson Laukka E, Small BJ, et al. A preclinical phase in vascular dementia: cognitive impairment three years before diagnosis. Dement Geri Cogn Dis 2004;18:233-239.
20. Rasquin SM, Lodder J, Verhey FR. Predictors of reversible mild cognitive impairment after stroke: a 2-year follow-up study. J Neurol Sci 2005;229-230:21-25.
21. Hochstenbach JB, den Otter R, Mulder TW. Cognitive recovery after stroke: a 2-year follow-up. Arch Phys Med Rehab 2003;84:1499-1504.
22. Ballard C, Rowan E, Stephens S, et al. Prospective follow-up study between 3 and 15 months after stroke: improvements and decline in cognitive function among dementia-free stroke survivors >75 years of age. Stroke 2003;34:2440-2444.
23. Patel M, Coshall C, Rudd AG, et al. Natural history of cognitive impairment after stroke and factors associated with its recovery. Clin Rehab 2003;17:158-166.
24. Sachdev PS, Brodaty H, Valenzuela MJ, et al. Progression of cognitive impairment in stroke patients. Neurol 2004;63:1618-1623.
25. de Koning I, van Kooten F, Dippel DW, et al. The CAMCOG: a useful screening instrument for dementia in stroke patients. Stroke 1998;29:2080-2086.
26. Wood RY, Giuliano KK, Bignell CU, et al. Assessing cognitive ability in research: use of MMSE with minority populations and elderly adults with low education levels. J Gerontol Nurs 2006;32:45-54.
27. Bohnstedt M, Fox PJ, Kohatsu ND. Correlates of Mini-Mental Status Examination scores among elderly demented patients: the influence of race-ethnicity. J Clin Epidemiol 1994;47:1381-1387.
28. Desmond DW, Moroney JT, Sano M, et al. Recovery of cognitive function after stroke. Stroke 1996;27:1798-1803.
29. van Exel E, de Craen AJ, Gussekloo J, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol 2002;51:716-721.
30. Atzmon G, Gabriely I, Greiner W, et al. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol Ser A-Biol Sci Med Sci 2002;57:M712-M715.
31. Elias MF, Sullivan LM, D'Agostino RB, et al. Homocysteine and cognitive performance in the Framingham Offspring Study: age is important. Am J Epidemiol 2005;162:644-653.
32. Nurk E, Refsum H, Tell SG, et al. Plasma total homocysteine and memory in the elderly: The Hordaland Homocysteine Study. Ann Neurol 2005;58:847-857.
33. Robbins MA, Elias MF, Budge MM, et al. Homocysteine, type 2 diabetes mellitus, and cognitive performance: The Maine-Syracuse Study. Clin Chem Lab Med 2005;43:1101-1106.
34. Weimar C, Ziegler A, Konig IR, et al. Predicting functional outcome and survival after acute ischemic stroke. J Neurol 2002;249:888-895.
35. Pniewski J, Chodakowska-Zebrowska M, Wozniak R, et al. Plasma homocysteine level and the course of ischemic stroke. Acta Neurobiol Exp 2003;63:127-130.
36. Mizrahi EH, Fleissig Y, Arad M, et al. Plasma homocysteine level and functional outcome of patients with ischemic stroke. Arch Phys Med Rehab 2005;86:60-63.
37. McCombe Waller S, Whitall J. Hand dominance and side of stroke affect rehabilitation in chronic stroke. Clin Rehab 2005;19:544-551.
38. Gillen R, Tennen H, McKee T. Unilateral spatial neglect: relation to rehabilitation outcomes in patients with right hemisphere stroke. Arch Phys Med Rehab 2005;86:763-767.
39. Chalmers J, MacMahon S. Perindopril protection against Recurrent Stroke Study (PROGRESS): interpretation and implementation. J Hypertens Suppl 2003;21:S9-S14.
40. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomized trial. J Fam Pract 2002;51:595.
41. van der Laan MJ, Robins JM. Unified methods for censored longitudinal data and causality. Springer Verlag: New York, 2003.
42. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics 2005;61:962-972.
43. Little RJA, Rubin DB. Statistical analysis with missing data. Wiley: New York, 1987.
44. Lezak M. Neuropsychological assessment (3rd Ed.). New York: Oxford University Press, 1995.
45. Galasko D, Abramson I, Corey-Bloom J, et al. Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a practice effect in Alzheimer's disease. Neurol 1993;43:1559-1563.
46. Polidori MC, Mattioli P, Aldred S, et al. Plasma antioxidant status, immunoglobulin G oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 2004;18:265-70.
47. Wada-Isoe K, Wakutani Y, Urakami K, et al. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients. Acta Neurol Scand 2004;110:124-127.
48. Moser DJ, Hoth KF, Robinson RG, et al. Blood vessel function and cognition in elderly patients with atherosclerosis. Stroke 2004;35:369-372.
49. Geroldi C, Ferrucci L, Bandinelli S, et al. InCHIANTI Study. Mild cognitive deterioration with subcortical features: prevalence, clinical characteristics, and association with cardiovascular risk factors in community-dwelling older persons. J Am Geriatr Soc 2003;51:1064-1071.
50. Sanossian N, Saver JL, Navab M, et al. High-density lipoprotein cholesterol. Stroke 2007;38:1104-1109.
51. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
52. Korczyn AD. Homocysteine, stroke and dementia. Stroke 2002;33:2343-2344.
53. McCaddon A, Hudson P, Davies G, et al. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 2001;12:309-313.
54. Geroldi C, Frisoni GB, Paolisso G, et al. Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol 2005;62:1067-1072.
55. Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 2002;438:1-14.
56. Denny JB, Polancurtain J, Wayner M, et al. Angiotensin-II blocks hippocampal long-term potentiation. Brain Res 1991;567:321-324.